Company Overview of Haemostatix Ltd.
Haemostatix Ltd. develops a peptide-based platform technology to develop a pipeline of products to treat surgical bleeding with further applications in tissue repair and regenerative medicine. Its pipeline includes PeproStat, a coagulant/haemostat that is applied directly to a wound during surgery to control bleeding. The company was founded in 2003 and is based in Nottingham, United Kingdom. As of May 24, 2016, Haemostatix Ltd. operates as a subsidiary of Ergomed plc.
Nottingham, NG1 1GF
Founded in 2003
44 11 5912 4512
Key Executives for Haemostatix Ltd.
Similar Private Companies By Industry
|Achilles Therapeutics Ltd.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Haemostatix Ltd., please visit www.haemostatix.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.